IMPACT OF TIMING FROM BLOOD SAMPLING TO PHARMACODYNAMIC ASSESSMENT ON MEASURES OF PLATELET REACTIVITY IN PATIENTS TREATED WITH P2Y12 RECEPTOR INHIBITORS

Several platelet function tests (PFT) are available to assess the pharmacodynamic (PD) effects of P2Y(12) inhibitors. However, there are technical variances between PFT, and P2Y(12) inhibitors differ in pharmacological properties. Manufactures of PFT recommend a time-frame within which assessments needs to be executed. However, if the timing from blood sampling to processing affects PD results is unknown. We conducted a prospective study assessing the impact of timing from blood sampling to processing on PD measures using three different PFT. We studied 60 aspirin-treated patients with coronary artery disease (CAD) on maintenance P2Y(12) inhibiting therapy [clopidogrel 75 mg/day (n=20), prasugrel 10 mg/day (n=20) and ticagrelor 90 mg bid (n=20)]. PD assessments (trough levels) were performed by VerifyNow P2Y12 (VN), light transmittance aggregometry (LTA) and vasodilator-stimulated phosphoprotein (VASP) at 30 minutes, 2 and 4 hours post-sampling; VASP was also performed at 24 hours. P2Y(12) reaction units (PRU) by VN significantly decreased over time with all P2Y(12) inhibitors (clopidogrel p<0.001; prasugrel p=0.016; ticagrelor p<0.001). PRU at 30 minutes and 2 hours were similar, but decreased at 4 hours. LTA showed consistent findings with VN. Conversely, PD measures as assessed by VASP were stable over time (p>0.1 for all P2Y(12) inhibitors). In conclusion, in CAD patients on maintenance therapy with P2Y(12) inhibitors, timing from blood sampling to processing significantly influences PD measures as assessed by VN and LTA, but not by VASP.